Lenalidomide mediated immune regulation in cancer immunotherapy

• Main Authors: Cher Chang, 張竹君
• Other Authors: Ming-Shen Dai
• Format: Others
• Language: zh-TW
• Published: 2011
• Online Access: http://ndltd.ncl.edu.tw/handle/22555319154780341874

碩士 === 中華科技大學 === 健康科技研究所在職專班 === 99 === Recent preclinical and clinical findings suggest that the immunomodulatory drug (IMiDs) Lenalidomide has dual mechanism of action, involving both the direct tumoricidal activity and immunomodulation, which can result in rapid and sustained control of Multiple myeloma (MM). Furthermore, its actions are believed to be mediated by apoptosis, anti-antigenic and anti-proliferative activity, and modulation of cytokine production (such as IL-2、IL-10、TNF-α、IL-1b、IL-6). Additionally, Lenalidomide has shown success in the stimulation of T-cells and natural killer cells (NK), thereby improving the cells’ immunity and cytotoxicity. In order to further investigate the effect of Lenalidomide in immune modulation, we examined the Lenalidomide-induced in vitro lymphocytes proliferation and gene expression changes through RNA array and cell proliferation. Its effect in macrophage polarization was also tested in tumor co-culture experiment. The results of the in vitro study demonstrated the effect of Lenalidomide in modulating cytokine production and T-cells activation. In addition, the in vivo study displayed the indirect effect in tumor cell growth. In conclusion, using Lenalidomide in the treatment of cancers appears a promising and viable option in modulating the tumor microenvironment.